Trial Details
RECRUITINGBasic Information
| Clinical ID | c825 |
|---|---|
| Identifier | NCT05995353 |
| Trial Title | A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: Risankizumab|DRUG: Risankizumab |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Phoenix |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2023-12-11 |
|---|---|
| Primary Completion Date | 2029-04 |
| Completion Date | 2029-04 |